Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
about
Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathwaysImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersN-Myc and L-Myc are essential for hair cell formation but not maintenanceLevels of active tyrosine kinase receptor determine the tumor response to ZalypsisInhibition of neuronal cell death after retinoic acid-induced down-regulation of P2X7 nucleotide receptor expression.Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model.Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesisA single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitorsChemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.EGFR inhibitor enhances cisplatin sensitivity of human glioma cells.Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.Synthesis, anticancer, and antibacterial activities of piplartine derivatives on cell cycle regulation and growth inhibition.
P2860
Q24299578-79449B89-9913-46F9-9353-8F6331A90EF7Q26751473-1543FA78-6888-427A-A571-94AA22B9441FQ28587989-ABDCF1E0-1E47-4A38-B7F9-AA4C159976B6Q33622731-473A00E9-08BB-4F52-9319-7DC929237CD8Q33637655-9A91D17A-69D1-424F-BEF3-8155D10A6A04Q34505680-00B7A715-0CE5-456A-88C6-52BAEAFA1A22Q35156047-5E55228B-3FEE-4C94-B944-32C63560D125Q35597039-B46FD695-C767-43AC-B7BF-B19AB6CCE470Q35999648-BADA35DC-B41D-48B1-B685-5EB67E08A9E6Q36280333-1BA34E89-90A6-4E13-B62E-37A6C5A0206CQ36480984-8911653E-04E4-4279-A2A0-E33330FFAD64Q37387342-A4521177-1A2D-462A-BCFB-4EDDB0017139Q38071119-E1E59410-19A3-4AA9-813E-C5BE9BB1B0C6Q39281507-1858792B-263F-4FC8-9673-F98CD03EFA15Q39427603-41E7A2B0-27FE-4348-8082-223F6990E0A6Q39589502-D81160D1-6558-40CE-91C9-E820C2C02C2CQ41022992-41711046-3B98-47F7-A64C-3267DE99D0B7Q41859828-D59F6F9D-8832-4C7E-A6D4-18CE3ED46EEAQ45065769-3C642307-9DAB-4237-A784-C13B49958C69Q53107381-D789F87B-5D37-45C3-A888-E4700530ABE1
P2860
Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cisplatin-resistant neuroblast ...... ent with EGFR-specific toxins.
@ast
Cisplatin-resistant neuroblast ...... ent with EGFR-specific toxins.
@en
type
label
Cisplatin-resistant neuroblast ...... ent with EGFR-specific toxins.
@ast
Cisplatin-resistant neuroblast ...... ent with EGFR-specific toxins.
@en
prefLabel
Cisplatin-resistant neuroblast ...... ent with EGFR-specific toxins.
@ast
Cisplatin-resistant neuroblast ...... ent with EGFR-specific toxins.
@en
P2093
P1476
Cisplatin-resistant neuroblast ...... ent with EGFR-specific toxins.
@en
P2093
Florian Rothweiler
Hans W Doerr
Hedwig E Deubzer
Jennifer Bliss
Jindrich Cinatl
Nora Hinsch
Sonja C Arnold
Winfried S Wels
P304
P356
10.1158/1078-0432.CCR-08-0821
P407
P577
2008-10-01T00:00:00Z